Browse our 650+ Publications​

Latest Publications

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.

San-Miguel J, et al.
Blood
January 2022
Authors and Affiliates
Jesus San-Miguel,1 Herve Avet-Loiseau, 2 Bruno Paiva,1 Shaji Kumar,3 Meletios A. Dimopoulos,4 Thierry Facon,5 Marıa-Victoria Mateos, 6Cyrille Touzeau,7 Andrzej Jakubowiak,8 Saad Z. Usmani,9 Gordon Cook,10 Michele Cavo,11 Hang Quach,12 Jon Ukropec,13 Priya Ramaswami,14 Huiling Pei,14 Mia Qi,15 Steven Sun,15 Jianping Wang,15 Maria Krevvata,16 Nikki DeAngelis,16 Christoph Heuck,16 Rian Van Rampelbergh,17 Anupa Kudva,15 Rachel Kobos,15 Ming Qi,16 and Nizar J. Bahlis,18 1Clınica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain; 2Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France; 3Department of Hematology, Mayo Clinic, Rochester,MN; 4National and Kapodistrian University of Athens, Athens, Greece; 5University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 6University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain; 7Hematology, University Hospital Hotel-Dieu, Nantes, France; 8University of Chicago Medical Center, Chicago, IL; 9Levine Cancer Institute/Atrium Health, Charlotte, NC; 10Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom; 11IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli, ” Universita di Bologna, Bologna, Italy; 12University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC; 13Janssen Global Medical Affairs, Horsham, PA; 14Janssen Research & Development, LLC, Titusville, NJ; 15Janssen Research & Development, LLC, Raritan, NJ; 16Janssen Research & Development, LLC, Spring House, PA; 17Janssen Research & Development, Beerse, Belgium; and 18Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

Lozano AX, et al.
Nature Medicine
January 2022
Authors and Affiliates
Alexander X Lozano #,1,2, Aadel A Chaudhuri #,3,4,5,6, Aishwarya Nene #,7, Antonietta Bacchiocchi 8, Noah Earland 9, Matthew D Vesely 8, Abul Usmani 9, Brandon E Turner 10, Chloé B Steen 10,11, Bogdan A Luca 12, Ti Badri 13, Gunsagar S Gulati 10, Milad R Vahid 10, Farnaz Khameneh 10, Peter K Harris 9, David Y Chen 14,15, Kavita Dhodapkar 16, Mario Sznol 17,18, Ruth Halaban 8,18, Aaron M Newman #,19,20; 1 Department of Materials Science and Engineering, Stanford University, Stanford, CA, USA. 2 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 3 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. aadel@wustl.edu. 4 Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA. aadel@wustl.edu. 5 Department of Computer Science & Engineering, Washington University, St. Louis, MO, USA. aadel@wustl.edu. 6 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. aadel@wustl.edu. 7 Yale School of Medicine, Yale University, New Haven, CT, USA. 8 Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA. 9 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. 10 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. 11 Department of Biomedical Data Science, Stanford University, Stanford, CA, USA. 12 Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, USA. 13 Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. 14 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. 15 Division of Dermatology, Washington University School of Medicine, St. Louis, MO, USA. 16 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, USA. 17 Department of Medicine, Division of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA. 18 Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA. 19 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. amnewman@stanford.edu. 20 Department of Biomedical Data Science, Stanford University, Stanford, CA, USA. amnewman@stanford.edu. # Contributed equally.

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab

Adusumilli PS, et al.
Cancer Discovery
January 2022
Authors and Affiliates
Prasad S Adusumilli 1,2,3, Marjorie G Zauderer 2,4, Isabelle Rivière 3,5, Stephen B Solomon 6, Valerie W Rusch 7, Roisin E O'Cearbhaill 2,8, Amy Zhu 7, Waseem Cheema 7, Navin K Chintala 7, Elizabeth Halton 2, John Pineda 2, Rocio Perez-Johnston 6, Kay See Tan 2,9, Bobby Daly 4, Jose A Araujo Filho 6, Daniel Ngai 7, Erin McGee 7, Alain Vincent 7, Claudia Diamonte 2, Jennifer L Sauter 10, Shanu Modi 2,11, Devanjan Sikder 5, Brigitte Senechal 5, Xiuyan Wang 5, William D Travis 10, Mithat Gönen 9, Charles M Rudin 4, Renier J Brentjens 2,3, David R Jones 7, Michel Sadelain 3; 1 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. adusumip@mskcc.org. 2 Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York. 4 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 5 Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York. 6 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 7 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 8 Gynecologic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 9 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 10 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 11 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

DJ‐1 depletion prevents immunoaging in T‐cell compartments

Zeng N, et al.
January 2022
Authors and Affiliates
Ni Zeng 1,2, Christophe M Capelle 1,2, Alexandre Baron 1, Takumi Kobayashi 1, Severine Cire 1, Vera Tslaf 1,2,3, Cathy Leonard 1, Djalil Coowar 4, Haruhiko Koseki 5,6, Astrid M Westendorf 7, Jan Buer 7, Dirk Brenner 1,4, Rejko Krüger 3,4,8, Rudi Balling 4, Markus Ollert 1,9, Feng Q Hefeng 1,7; 1 Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg. 2 Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. 3 Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg. 4 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg. 5 Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. 6 AMED-CREST, Japanese Agency for Medical Research and Development, Yokohama, Japan. 7 Institute of Medical Microbiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 8 Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg. 9 Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), University of Southern Denmark, Odense, Denmark.

SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans

Mudd PA, et al.
Cell
January 2022
Authors and Affiliates
Philip A Mudd 1, Anastasia A Minervina 2, Mikhail V Pogorelyy 2, Jackson S Turner 3, Wooseob Kim 3, Elizaveta Kalaidina 4, Jan Petersen 5, Aaron J Schmitz 3, Tingting Lei 3, Alem Haile 6, Allison M Kirk 2, Robert C Mettelman 2, Jeremy Chase Crawford 2, Thi H O Nguyen 7, Louise C Rowntree 7, Elisa Rosati 8, Katherine A Richards 9, Andrea J Sant 9, Michael K Klebert 6, Teresa Suessen 10, William D Middleton 10, SJTRC Study Team; Joshua Wolf 11, Sharlene A Teefey 10, Jane A O'Halloran 12, Rachel M Presti 13, Katherine Kedzierska 7, Jamie Rossjohn 14, Paul G Thomas 15, Ali H Ellebedy 16; 1 Department of Emergency Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO 63110, USA. Electronic address: pmudd@wustl.edu. 2 Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. 3 Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA. 4 Division of Allergy and Immunology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA. 5 Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia. 6 Clinical Trials Unit, Washington University School of Medicine, Saint Louis, MO 63110, USA. 7 Department of Microbiology and Immunology, University of Melbourne, at Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3052, Australia. 8 Institute of Clinical Molecular Biology, Christian-Albrecht University of Kiel, Kiel 24105, Germany. 9 David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA. 10 Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO 63110, USA. 11 Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. 12 Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA. 13 Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO 63110, USA; Clinical Trials Unit, Washington University School of Medicine, Saint Louis, MO 63110, USA; Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO 63110, USA. 14 Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia; Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff CF14 4XN, UK. 15 Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: paul.thomas@stjude.org. 16 Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO 63110, USA. Electronic address: ellebedy@wustl.edu.

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Smith EL, et al.
Cancer Immunology Research
January 2022
Authors and Affiliates
Eric L Smith 1,2, Sham Mailankody 3,2, Mette Staehr 3, Xiuyan Wang 4, Brigitte Senechal 4, Terence J Purdon 3, Anthony F Daniyan 3,5, Mark B Geyer 3,5, Aaron D Goldberg 5, Elena Mead 3,6, Bianca D Santomasso 3,7,8, Jonathan Landa 9, Andreas Rimner 10, Isabelle Riviere 4, Ola Landgren 2, Renier J Brentjens 1,5; 1 Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. smithe3@mskcc.org brentjer@mskcc.org. 2 Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3 Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 4 Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York. 5 Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 6 Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 7 Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York. 8 Parker Institute for Cancer Immunotherapy, San Francisco, California. 9 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 10 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed

Shibata T, et al.
Frontiers in Immunology
January 2022
Authors and Affiliates
Takeo Shibata 1,2, Sumit Shah 1, Teresa Evans 1, Hannah Coleman 1, Benjamin J Lieblong 1, Horace J Spencer 3, Charles M Quick 1, Toshiyuki Sasagawa 2, Owen W Stephens 4, Erich Peterson 4, Donald Johann Jr 5, Yong-Chen Lu 1, Mayumi Nakagawa 1; 1 Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, United States. 2 Department of Obstetrics and Gynecology, Kanazawa Medical University, Uchinada, Japan. 3 Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, United States. 4 Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, United States. 5 Department of Internal Medicine (Hematology-Oncology Division), University of Arkansas for Medical Sciences, Little Rock, AR, United States.

The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders

Li D, et al.
January 2022
Authors and Affiliates
Dalin Li, Alexander Xu, Emebet Mengesha, Rebecca Elyanow, Rachel M Gittelman, Heidi Chapman, John C Prostko, Edwin C Frias, James L Stewart, Valeriya Pozdnyakova, Philip Debbas, Angela Mujukian, Arash A Horizon, Noah Merin, Sandy Joung, Gregory J Botwin, Kimia Sobhani, Jane C Figueiredo, Susan Cheng, Ian M Kaplan, Dermot P B McGovern, Akil Merchant, Gil Y Melmed, Jonathan Braun;

A Framework to Identify Antigen-Expanded T Cell Receptor Clusters Within Complex Repertoires

Ceglia V, et al.
Frontiers in Immunology
January 2022
Authors and Affiliates
Valentina Ceglia 1,2,3, Erin J Kelley 4, Annalee S Boyle 4, Sandra Zurawski 1,3, Heather L Mead 4, Caroline E Harms 4, Jean-Philippe Blanck 1, Anne-Laure Flamar 1,2,3, Jung Hwa Kirschman 4, Paul Ogongo 5, Joel D Ernst 5, Yves Levy 2,3, Gerard Zurawski 1,3, John A Altin 4; 1 Baylor Institute for Immunology Research, Dallas, TX, United States. 2 Université Paris-Est Créteil, Sciences de la Vie et de la Santé, Créteil, France. 3 Vaccine Research Institute, INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France. 4 Translational Genomics Research Institute, Flagstaff, AZ, United States. 5 Department of Medicine, Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States.
Previous Next